Literature DB >> 30513344

A brief introduction of IgG-like bispecific antibody purification: Methods for removing product-related impurities.

Yifeng Li1.   

Abstract

Bispecific antibodies (bsAbs) are antibodies that can simultaneously bind two distinct targets or epitopes. Their dual-targeting capacity offers expanded therapeutic potential. Currently there is a strong interest in design and production of bsAbs to achieve improved efficacy through novel mechanisms of action. However, due to the co-expression of up to four distinct polypeptide chains or assembly involving chains with extended length (in the appended IgG format), recombinant production of IgG-like bsAbs is often accompanied with increased level of product-related impurities (byproducts and aggregates) resulting from heavy chain homodimerization, heavy chain-light chain mispairing, unbalanced expression of different chains and intermolecular misassociation. As some of the byproducts display close similarity to the target bsAb, their removal poses significant challenges to the downstream processing. This article reviews methods that can effectively remove product-related impurities in IgG-like bsAb purification.
Copyright © 2018 Elsevier Inc. All rights reserved.

Keywords:  Aggregates; Bispecific antibody (bsAb); Half-antibody; Heterodimer; Homodimer; Hydroxyapatite (HA); Mixed-mode resin; Single-chain variable fragment (scFv)

Mesh:

Substances:

Year:  2018        PMID: 30513344     DOI: 10.1016/j.pep.2018.11.011

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc.

Authors:  Fabian Richter; Oliver Seifert; Andreas Herrmann; Klaus Pfizenmaier; Roland E Kontermann
Journal:  MAbs       Date:  2019-03-31       Impact factor: 5.857

2.  Productivity and quality improvement for a symmetric bispecific antibody through the application of intensified perfusion cell culture.

Authors:  Yongjun Qin; Rongmei Ma; Yang Li; Yifeng Li; Gong Chen; Weichang Zhou
Journal:  Antib Ther       Date:  2022-05-03

Review 3.  Current trends and challenges in the downstream purification of bispecific antibodies.

Authors:  Serene W Chen; Wei Zhang
Journal:  Antib Ther       Date:  2021-05-07

4.  Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.

Authors:  Huicheng Liu; Lili Bai; Liu Huang; Na Ning; Lin Li; Yijia Li; Xuejiao Dong; Qiuyang Du; Minghui Xia; Yufei Chen; Likun Zhao; Yanhu Li; Qingwu Meng; Jing Wang; Yaqi Duan; Jie Ming; Andy Qingan Yuan; Xiang-Ping Yang
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

5.  Application of IgG antibody titer and subtype in diagnosis and severity assessment of hemolytic disease of the newborn.

Authors:  Zijun Ding; Xinhua Zhang; Hai Li
Journal:  Transl Pediatr       Date:  2022-09

6.  Use of magnetic particles in the purification of IgM antibodies against Taenia solium.

Authors:  L Agueda Perez; Yesenia Castillo; Cindy Espinoza; Luz M Toribio; Yesica Santos; Kevin S Martel; Patricia P Wilkins; Javier A Bustos; Hector H García; Yagahira E Castro-Sesquen
Journal:  Rev Peru Med Exp Salud Publica       Date:  2020-06-08

7.  An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.

Authors:  Norbert Furtmann; Marion Schneider; Nadja Spindler; Bjoern Steinmann; Ziyu Li; Ingo Focken; Joachim Meyer; Dilyana Dimova; Katja Kroll; Wulf Dirk Leuschner; Audrey Debeaumont; Magali Mathieu; Christian Lange; Werner Dittrich; Jochen Kruip; Thorsten Schmidt; Joerg Birkenfeld
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.